Abstract
Acquired immunodeficiency syndrome (AIDS) remains, after 25 years of its discovery, as one of the major threats to human life. Reverse Transcriptase is an essential enzyme for virus replication, and therefore constitutes a major target in HIV-1 therapy. Among the different types of drugs targeting RT, the nonnucleoside reverse transcriptase inhibitors (NNRTIs) act by binding in an induced- fit allosteric pocket. In this review, we explore the several NNRTIs structures and binding interactions, as well as their mechanisms of action. The conformational changes that they cause in RT and their effects on the topology of the active site are discussed. The emergence of mutant, resistant viruses is analysed, focussing on the mutations responsible for the loss of antiviral efficacy of NNRTIs. Explanations for the role of those mutations are presented. Emergent drugs in the pipeline, together with the underlying strategies for drug development, are also analysed.
Current Medicinal Chemistry
Title: The Current Status of the NNRTI Family of Antiretrovirals Used Against HIV Infection
Volume: 15 Issue: 11
Author(s): Silvia Martins, Maria Joao Ramos and Pedro Alexandrino Fernandes
Affiliation:
Abstract: Acquired immunodeficiency syndrome (AIDS) remains, after 25 years of its discovery, as one of the major threats to human life. Reverse Transcriptase is an essential enzyme for virus replication, and therefore constitutes a major target in HIV-1 therapy. Among the different types of drugs targeting RT, the nonnucleoside reverse transcriptase inhibitors (NNRTIs) act by binding in an induced- fit allosteric pocket. In this review, we explore the several NNRTIs structures and binding interactions, as well as their mechanisms of action. The conformational changes that they cause in RT and their effects on the topology of the active site are discussed. The emergence of mutant, resistant viruses is analysed, focussing on the mutations responsible for the loss of antiviral efficacy of NNRTIs. Explanations for the role of those mutations are presented. Emergent drugs in the pipeline, together with the underlying strategies for drug development, are also analysed.
Export Options
About this article
Cite this article as:
Martins Silvia, Ramos Joao Maria and Fernandes Alexandrino Pedro, The Current Status of the NNRTI Family of Antiretrovirals Used Against HIV Infection, Current Medicinal Chemistry 2008; 15 (11) . https://dx.doi.org/10.2174/092986708784221467
DOI https://dx.doi.org/10.2174/092986708784221467 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patents of Pentoxifylline Administration on Some Diseases and Chronic Wounds
Recent Patents on Regenerative Medicine Towards More Successful Gene Therapy Clinical Trials for β-Thalassemia
Current Molecular Medicine Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Keeping A Breast of Recent Developments in Cancer Metabolism
Current Drug Targets Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry Recent Trials for FTY720 (Fingolimod): A New Generation of Immunomodulators Structurally Similar to Sphingosine
Reviews on Recent Clinical Trials Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry From TGF-β to Cancer Therapy
Current Drug Targets Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Current Molecular Medicine Endothelial Progenitor Cells as Molecular Targets in Vascular Senescence and Repair
Current Stem Cell Research & Therapy Propofol: Therapeutic Indications and Side-Effects
Current Pharmaceutical Design Aspartic Protease Inhibitors as Potential Anti-Candida albicans Drugs: Impacts on Fungal Biology, Virulence and Pathogenesis
Current Medicinal Chemistry Exfoliated Epithelial Cells: A Non-Invasive way to Evaluate the Physiological State of Gastrointestinal Epithelium
Recent Patents on Biomedical Engineering (Discontinued) 5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry Mouse Models of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Current Pharmaceutical Design Nitric Oxide in Normal and Preeclamptic Pregnancy
Current Pharmaceutical Biotechnology Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon
CNS & Neurological Disorders - Drug Targets Therapeutic Potential of the Modulation of Sphingosine-1-Phosphate Receptors
Current Medicinal Chemistry Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology Psychotropic Medications and the Treatment of Human Prion Diseases
CNS & Neurological Disorders - Drug Targets